Velcade in MALT Lymphoma Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Bortezomib for treatment of disseminated MALT lymphoma or at relapse following HP -eradication,or chemotherapy or radiation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Vienna
• Treatments: Bortezomib

Criteria

Inclusion Criteria:

• patients with histologically confirmed MALT lymphoma with measurable disease (stage I-IV)

• with first or greater relapse after HP-eradication, radiation or chemotherapy ,

• age > 18 years

• must be able to tolerate therapy and have adequate cardiac, renal and hepatic function

• ECOG status of <_ 2

• must be capable of understanding the purpose of the study and given written informed consent